Literature DB >> 1913694

Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers.

R F Boynton1, Y Huang, P L Blount, B J Reid, W H Raskind, R C Haggitt, C Newkirk, J H Resau, J Yin, T McDaniel, S J Meltzer.   

Abstract

Abnormalities in the retinoblastoma tumor suppressor gene (Rb) have been observed in a large number of human cancers. Loss of heterozygosity is a common mode of allelic inactivation of Rb and other tumor suppressor genes. We investigated DNA from 61 primary human esophageal tumors for loss of heterozygosity at the Rb locus using a polymerase chain reaction-based restriction fragment length polymorphism assay. Of informative cases, we found loss of heterozygosity in 14 of 26 (54%) squamous cell carcinomas and 5 of 14 (36%) adenocarcinomas. These data support the hypothesis that Rb inactivation is involved in the pathogenesis and/or progression of esophageal cancer.

Entities:  

Mesh:

Year:  1991        PMID: 1913694

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 2.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

3.  Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy.

Authors:  Y Shimada; M Imamura; I Shibagaki; H Tanaka; T Miyahara; M Kato; K Ishizaki
Journal:  Ann Surg       Date:  1997-08       Impact factor: 12.969

4.  Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers.

Authors:  R F Boynton; P L Blount; J Yin; V L Brown; Y Huang; Y Tong; T McDaniel; C Newkirk; J H Resau; W H Raskind; R C Haggitt; B J Reid; S J Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

5.  Characterisation of telomerase immortalised normal human oesophageal squamous cells.

Authors:  C P Morales; K G Gandia; R D Ramirez; W E Wright; J W Shay; S J Spechler
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

6.  Localization of the CDKN4/p27Kip1 gene to human chromosome 12p12.3.

Authors:  E Martin; V Cacheux; H Cavé; J M Lapierre; D Le Paslier; B Grandchamp
Journal:  Hum Genet       Date:  1995-12       Impact factor: 4.132

7.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer.

Authors:  W Jiang; Y J Zhang; S M Kahn; M C Hollstein; R M Santella; S H Lu; C C Harris; R Montesano; I B Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Authors:  Tadayuki Akagi; Tetsuo Ito; Motohiro Kato; Zhe Jin; Yulan Cheng; Takatsugu Kan; Go Yamamoto; Alexandru Olaru; Norihiko Kawamata; Jessica Boult; Harmik J Soukiasian; Carl W Miller; Seishi Ogawa; Stephen J Meltzer; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

9.  Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma.

Authors:  D M Muirhead; H T Hoffman; R A Robinson
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

10.  Molecular and cellular features of esophageal cancer cells.

Authors:  T Nishihira; Y Hashimoto; M Katayama; S Mori; T Kuroki
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.